Daito Pharmaceutical Co.,Ltd. (TYO:4577)

Daito Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is June - May.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	May 31, 2026	May 31, 2025	May 31, 2024	May 31, 2023	May 31, 2022
Cash & Equivalents	954	2,207	2,727	3,607	4,381
Cash & Short-Term Investments	954	2,207	2,727	3,607	4,381
Cash Growth	-56.77%	-19.07%	-24.40%	-17.67%	29.92%
Accounts Receivable	12,821	20,254	15,441	17,654	16,146
Other Receivables	6,134	-	1,292	-	-
Receivables	18,955	20,254	16,733	17,654	16,146
Inventory	16,439	18,412	20,890	18,238	16,820
Other Current Assets	281	835	1,110	1,164	562
Total Current Assets	36,629	41,708	41,460	40,663	37,909
Property, Plant & Equipment	30,674	31,826	31,972	25,837	23,116
Long-Term Investments	2,193	3,579	3,464	3,169	2,958
Other Intangible Assets	1,712	531	490	377	386
Long-Term Deferred Tax Assets	181	359	320	504	570
Other Long-Term Assets	1,902	1	2	2	-
Total Assets	73,291	78,004	77,708	70,552	64,939

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	May 31, 2026	May 31, 2025	May 31, 2024	May 31, 2023	May 31, 2022
Accounts Payable	6,486	8,266	8,699	8,172	7,864
Accrued Expenses	506	1,086	1,051	1,091	1,170
Short-Term Debt	-	-	-	69	11
Current Portion of Long-Term Debt	2,815	3,099	2,099	1,429	1,189
Current Portion of Leases	506	358	275	15	-
Current Income Taxes Payable	593	3,348	4,681	4,288	3,319
Other Current Liabilities	3,092	892	1,700	364	516
Total Current Liabilities	13,998	17,049	18,505	15,428	14,069
Long-Term Debt	3,753	6,569	4,669	3,368	2,247
Long-Term Leases	2,220	1,859	1,676	77	-
Pension & Post-Retirement Benefits	33	169	320	497	755
Long-Term Deferred Tax Liabilities	65	30	32	31	32
Other Long-Term Liabilities	286	261	242	180	165
Total Liabilities	20,355	25,937	25,444	19,581	17,268

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	May 31, 2026	May 31, 2025	May 31, 2024	May 31, 2023	May 31, 2022
Common Stock	7,186	7,186	7,186	7,186	7,031
Additional Paid-In Capital	7,072	7,072	7,072	7,072	6,917
Retained Earnings	36,970	37,179	37,087	35,006	32,338
Treasury Stock	-128	-749	-990	-124	-13
Comprehensive Income & Other	1,790	1,315	1,713	1,532	1,031
Total Common Equity	52,890	52,003	52,068	50,672	47,304
Minority Interest	46	64	196	299	367
Shareholders' Equity	52,936	52,067	52,264	50,971	47,671
Total Liabilities & Equity	73,291	78,004	77,708	70,552	64,939

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	May 31, 2026	May 31, 2025	May 31, 2024	May 31, 2023	May 31, 2022
Total Debt	9,294	11,885	8,719	4,958	3,447
Net Cash (Debt)	-8,340	-9,678	-5,992	-1,351	934
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-283.53	-318.14	-190.94	-42.68	30.50
Filing Date Shares Outstanding	28.74	29.99	30.59	31.61	31.7
Total Common Shares Outstanding	28.74	29.99	30.59	31.61	31.43
Working Capital	22,631	24,659	22,955	25,235	23,840
Book Value Per Share	1840.05	1734.24	1702.33	1603.24	1504.87
Tangible Book Value	51,178	51,472	51,578	50,295	46,918
Tangible Book Value Per Share	1780.49	1716.53	1686.31	1591.31	1492.59
Order Backlog	-	5,840	5,417	5,223	7,585

Data Source: S&P Global Market Intelligence Last updated: May 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 21, 2026

Data Sources Report a data error